FDA Alerts
FDA Allows Marketing of First A1c Test Labeled for Diagnosing Diabetes
Today the US Food and Drug Administration announced that it is allowing marketing of the COBAS INTEGRA 800 Tina-quant HbA1cDx assay (Tina-quant HbA1cDx assay) for the diagnosis of diabetes by healthcare professionals.
FDA Approves Invokana to Treat Type 2 Diabetes
The US Food and Drug Administration today approved Invokana (canaglifozin) tablets, used with diet and exercise, to improve glycemic control in adults with type 2 diabetes.
FDA Investigating Risk of Pancreatitis in Type 2 Diabetes Meds
The US Food and Drug Administration (FDA) is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis, or inflammation of the pancreas, and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics.
FDA Approves Three New Drug Treatments for Type 2 Diabetes
The US Food and Drug Administration today approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets.
Generic Actos to Treat Type 2 Diabetes
The U.S. Food and Drug Administration (FDA) today approved the first generic version of Actos ( pioglitazone hydrochloride) tablets. Along with diet and exercise, pioglitazone is used to improve blood glucose control in adults with type 2 diabetes.
FDA: Blood Pressure Medication Warning
The U.S. Food and Drug Administration (FDA) is warning of possible risks when using blood pressure medicines containing aliskiren with other drugs called angiotensin converting enzyme inhibitors ( ACEIs ) and angiotensin receptor blockers ( ARBs ) in patients with diabetes or kidney (renal) impairment.
FDA Drug Safety Communication: Tekturna
The U.S. Food and Drug Administration (FDA) is warning of possible risks when using blood pressure medicines containing aliskiren with other drugs called angiotensin converting enzyme inhibitors ( ACEIs ) and angiotensin receptor blockers ( ARBs ) in patients with diabetes or kidney (renal) impairment.
FDA Drug Safety Communication: Rosiglitazone-containing Medicines
The U.S. Food and Drug Administration (FDA) is informing the public of new restrictions to the prescribing and use of rosiglitazone-containing medicines.
FDA approves new treatment for Type 2 diabetes
The U.S. Food and Drug Administration today approved Tradjenta ( linagliptin ) tablets, used with diet and exercise, to improve blood glucose control in adults with Type 2 diabetes.
New Diabetes Drug
As diabetes becomes a bigger and bigger problem, it is welcome news when new treatments for the disease become available. The FDA has approved a new drug to help patients with type 2 diabetes control their blood sugar.